Unknown

Dataset Information

0

Salvianolic Acid B in Microemulsion Formulation Provided Sufficient Hydration for Dry Skin and Ameliorated the Severity of Imiquimod-Induced Psoriasis-Like Dermatitis in Mice.


ABSTRACT: Psoriasis is a chronic inflammatory skin disorder with a pathogenesis involving the interleukin-23/interleukin-17 axis. Salvianolic acid B exerts several pharmacological effects, such as antioxidation, anti-inflammation, and antitumor effects. The anti-psoriatic effects of salvianolic acid B have not been reported. In this study, we aimed to determine the optimum vehicle for salvianolic acid B, investigate its therapeutic effect on psoriatic-like skin conditions, and explore its underlying mechanisms of action. BALB/c mice were administered topical imiquimod to induce psoriasis-like skin and were then randomly assigned to control, vehicle control, salvianolic acid B in vehicles, and 0.25% desoximetasone ointment treatment groups. Barrier function, cytokine expression, histology assessment, and disease severity were evaluated. The results showed that salvianolic acid B-containing microemulsion alleviated disease severity, reduced acanthosis, and inhibited interleukin-23/interleukin-17 (IL-23/IL-17) cytokines, epidermal proliferation, and increased skin hydration. Our study suggests that salvianolic acid B represents a possible new therapeutic drug for the treatment of psoriasis. In addition, such formulation could obtain high therapeutic efficacy in addition to providing sufficient hydration for dry skin.

SUBMITTER: Guo JW 

PROVIDER: S-EPMC7284938 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7471623 | biostudies-literature
| S-EPMC9785382 | biostudies-literature
| S-EPMC7072797 | biostudies-literature
| S-EPMC9996901 | biostudies-literature
2022-12-26 | GSE214837 | GEO
2022-12-27 | GSE214836 | GEO
| S-EPMC8114823 | biostudies-literature
2022-12-27 | GSE214835 | GEO
| S-EPMC7246652 | biostudies-literature
| S-EPMC4170002 | biostudies-literature